MedTrace Logo

Effects of Phosphatidylserine and DHA on Cognitive Performance in Children With ADHD

NCT07521449 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-13

No results posted yet for this study

Summary

This study aimed to evaluate the effects of different phosphatidylserine (PS) formulations, with or without docosahexaenoic acid (DHA), on cognitive performance in children diagnosed with attention-deficit/hyperactivity disorder (ADHD) or presenting with clinically significant subthreshold ADHD symptoms.

A total of 45 medication-naïve children aged 10-14 years were randomly assigned to one of four groups: placebo, PS capsule (PS + DHA), PS sachet (PS without DHA), or PS Plus capsule (higher-dose PS + DHA). The intervention period was eight weeks.

Cognitive performance was assessed at baseline and after the intervention using the MOXO continuous performance test and the Stroop test. The study aimed to compare the effects of different PS formulations on attention, impulsivity, hyperactivity, and executive function.

Conditions

  • Attention Deficit Hyperactivity Disorder (ADHD)
  • ADHD

Interventions

OTHER

Placebo

Placebo formulation identical in appearance and administration to active supplements.

DIETARY_SUPPLEMENT

Phosphatidylserine-Omega3

Capsule containing 100 mg phosphatidylserine and 17.78 mg DHA administered once daily for 8 weeks.

DIETARY_SUPPLEMENT

Phosphatidylserine-Omega3

Sachet formulation containing 117.78 mg phosphatidylserine without DHA administered once daily for 8 weeks.

DIETARY_SUPPLEMENT

DHA Omega-3

Capsule containing 150 mg phosphatidylserine and 26.67 mg DHA administered once daily for 8 weeks.

Sponsors & Collaborators

  • Çağlar Charles Daniel Jaicks

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-30
Primary Completion
2024-06-01
Completion
2025-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07521449 on ClinicalTrials.gov